KR102523019B1 - 항-a베타 항체 및 이의 용도 - Google Patents
항-a베타 항체 및 이의 용도 Download PDFInfo
- Publication number
- KR102523019B1 KR102523019B1 KR1020207034600A KR20207034600A KR102523019B1 KR 102523019 B1 KR102523019 B1 KR 102523019B1 KR 1020207034600 A KR1020207034600 A KR 1020207034600A KR 20207034600 A KR20207034600 A KR 20207034600A KR 102523019 B1 KR102523019 B1 KR 102523019B1
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- sequence
- antibody
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678080P | 2018-05-30 | 2018-05-30 | |
| US62/678,080 | 2018-05-30 | ||
| PCT/US2019/034259 WO2019231957A1 (en) | 2018-05-30 | 2019-05-29 | Anti-abeta antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20210041535A KR20210041535A (ko) | 2021-04-15 |
| KR102523019B1 true KR102523019B1 (ko) | 2023-04-18 |
Family
ID=68694402
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020207034600A Active KR102523019B1 (ko) | 2018-05-30 | 2019-05-29 | 항-a베타 항체 및 이의 용도 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11084873B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3801618A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7210612B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102523019B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN112601550B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3100896C (cg-RX-API-DMAC7.html) |
| TW (1) | TWI721440B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019231957A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120288896A1 (en) | 2005-12-12 | 2012-11-15 | Ac Immune S.A. | Nucleic acid molecules encoding anti-amyloid-beta antibodies |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101325972B (zh) * | 2005-12-12 | 2020-06-16 | Ac免疫有限公司 | 具有治疗性质的Aβ1-42特异性单克隆抗体 |
| US8003097B2 (en) | 2007-04-18 | 2011-08-23 | Janssen Alzheimer Immunotherapy | Treatment of cerebral amyloid angiopathy |
| EP2527369A3 (en) * | 2007-09-13 | 2012-12-19 | University Of Zurich Prorektorat Forschung | Monoclonal amyloid beta (abeta)-specific antibody and uses thereof |
| CN104109208A (zh) * | 2007-11-14 | 2014-10-22 | 中外制药株式会社 | 使用抗gpr49抗体的癌症的诊断和治疗 |
| AU2008322523B2 (en) * | 2007-11-16 | 2013-10-10 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| WO2011016238A1 (en) * | 2009-08-06 | 2011-02-10 | Immunas Pharma, Inc. | Antibodies that specifically bind to a beta oligomers and use thereof |
| EP2928494A4 (en) | 2012-12-07 | 2016-11-02 | Biogen Internat Neuroscience Gmbh | METHOD FOR REDUCING AMYLOIDER PLAQUE OF BRAIN WITH ANTI-ASS ANTIBODIES |
| US9879076B2 (en) * | 2013-03-15 | 2018-01-30 | Ramot At Tel Aviv University Ltd. | Methods and compositions with immune therapy for treatment of dementia |
| MX378944B (es) * | 2014-04-18 | 2025-03-10 | Univ New York State Res Found | Anticuerpos de antígeno anti-tf humanizado. |
| CA3004482A1 (en) * | 2015-11-09 | 2017-05-18 | Neil R. Cashman | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
| PL3430397T3 (pl) * | 2016-03-14 | 2022-04-04 | Biogen International Neuroscience Gmbh | Oznaczenie fagocytozy zależnej od przeciwciał do wiarygodnych pomiarów wychwytu zagregowanych białek |
-
2019
- 2019-05-29 KR KR1020207034600A patent/KR102523019B1/ko active Active
- 2019-05-29 EP EP19811193.2A patent/EP3801618A4/en active Pending
- 2019-05-29 WO PCT/US2019/034259 patent/WO2019231957A1/en not_active Ceased
- 2019-05-29 CN CN201980036565.6A patent/CN112601550B/zh active Active
- 2019-05-29 JP JP2020566267A patent/JP7210612B2/ja active Active
- 2019-05-29 CA CA3100896A patent/CA3100896C/en active Active
- 2019-05-30 TW TW108118733A patent/TWI721440B/zh active
- 2019-05-30 US US16/426,585 patent/US11084873B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120288896A1 (en) | 2005-12-12 | 2012-11-15 | Ac Immune S.A. | Nucleic acid molecules encoding anti-amyloid-beta antibodies |
Non-Patent Citations (2)
| Title |
|---|
| J Neuroimmunol, 1;88(1-2):85-90(1998) |
| PLOS ONE 9(3):e90857(2014.03.)* |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019277171A1 (en) | 2020-12-03 |
| JP2021525512A (ja) | 2021-09-27 |
| CN112601550B (zh) | 2023-12-08 |
| EP3801618A4 (en) | 2022-07-27 |
| JP7210612B2 (ja) | 2023-01-23 |
| TWI721440B (zh) | 2021-03-11 |
| US20190367593A1 (en) | 2019-12-05 |
| WO2019231957A1 (en) | 2019-12-05 |
| TW202033549A (zh) | 2020-09-16 |
| US11084873B2 (en) | 2021-08-10 |
| KR20210041535A (ko) | 2021-04-15 |
| CA3100896C (en) | 2023-08-29 |
| CA3100896A1 (en) | 2019-12-05 |
| EP3801618A1 (en) | 2021-04-14 |
| CN112601550A (zh) | 2021-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101990096B1 (ko) | 알파-시누클레인 항체와 그것의 용도 | |
| AU2013302540B2 (en) | Methods of treating a tauopathy | |
| JP7357834B2 (ja) | アミロイドベータに対する抗体 | |
| JP7173618B2 (ja) | アルファ-シヌクレインに対する抗体およびその用途 | |
| US10772969B2 (en) | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto | |
| CN121873233A (zh) | 用于治疗和诊断的新分子 | |
| US20230141177A1 (en) | Antibodies to misfolded amyloid beta | |
| US11084873B2 (en) | Anti-Abeta antibodies and uses thereof | |
| US12286469B2 (en) | Humanized antibodies binding to amyloid-beta (A-beta) | |
| JP2023086132A (ja) | アミロイドベータに対する抗体 | |
| CN114945592A (zh) | 抗-α-突触核蛋白单克隆抗体及其使用方法 | |
| JP2026503664A (ja) | 抗aベータ抗体を用いた神経障害の治療方法 | |
| US20250289877A1 (en) | Antibodies to Amyloid Beta | |
| HK40040248A (en) | Anti-abeta antibodies and uses thereof | |
| HK40040248B (en) | Anti-abeta antibodies and uses thereof | |
| EA053271B1 (ru) | Анти-aбета антитела | |
| HK40017344A (en) | Antibodies to amyloid beta | |
| HK40017344B (en) | Antibodies to amyloid beta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PA0302 | Request for accelerated examination |
St.27 status event code: A-1-2-D10-D17-exm-PA0302 St.27 status event code: A-1-2-D10-D16-exm-PA0302 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE) Year of fee payment: 4 |